- Home
- TCRT vs THAR Comparison
TCRT vs THAR Comparison
Compare TCRT & THAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TCRT
- THAR
- Stock Information
- Founded
- TCRT 1998
- THAR 2017
- Country
- TCRT United States
- THAR United States
- Employees
- TCRT N/A
- THAR N/A
- Industry
- TCRT Biotechnology: Pharmaceutical Preparations
- THAR Biotechnology: Pharmaceutical Preparations
- Sector
- TCRT Health Care
- THAR Health Care
- Exchange
- TCRT Nasdaq
- THAR Nasdaq
- Market Cap
- TCRT 3.8M
- THAR 3.3M
- IPO Year
- TCRT N/A
- THAR 2022
- Fundamental
- Price
- TCRT $3.03
- THAR $1.51
- Analyst Decision
- TCRT
- THAR Strong Buy
- Analyst Count
- TCRT 0
- THAR 1
- Target Price
- TCRT N/A
- THAR $17.00
- AVG Volume (30 Days)
- TCRT 12.3K
- THAR 26.3K
- Earning Date
- TCRT 05-15-2025
- THAR 05-12-2025
- Dividend Yield
- TCRT N/A
- THAR N/A
- EPS Growth
- TCRT N/A
- THAR N/A
- EPS
- TCRT N/A
- THAR N/A
- Revenue
- TCRT $11,000.00
- THAR N/A
- Revenue This Year
- TCRT $5,680,500.00
- THAR N/A
- Revenue Next Year
- TCRT N/A
- THAR N/A
- P/E Ratio
- TCRT N/A
- THAR N/A
- Revenue Growth
- TCRT 83.33
- THAR N/A
- 52 Week Low
- TCRT $1.31
- THAR $0.95
- 52 Week High
- TCRT $11.00
- THAR $6.39
- Technical
- Relative Strength Index (RSI)
- TCRT 60.98
- THAR 54.61
- Support Level
- TCRT $2.50
- THAR $1.41
- Resistance Level
- TCRT $2.80
- THAR $1.64
- Average True Range (ATR)
- TCRT 0.21
- THAR 0.11
- MACD
- TCRT 0.01
- THAR 0.01
- Stochastic Oscillator
- TCRT 98.31
- THAR 63.86
About TCRT Alaunos Therapeutics Inc.
Alaunos Therapeutics Inc is a clinical-stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. It strikes cancer at its core by engineering cell therapies that target Neoantigens arising from genomic mutations. It has a single reportable and operating segment related to biopharmaceutical research and development.
About THAR Tharimmune Inc.
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.